Lymphangiogenesis in haematological malignancies

Leukemia Research

Volumn 33, Issue 6, 2009, Pages 753-755

  Ribatti, Domenico ^a  

^a UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

Author keywords

Haematological malignancies; Lymphangiogenesis; Metastasis

Indexed keywords

ANGIOPOIETIN 1; ANGIOPOIETIN 2; ANGIOPOIETIN RECEPTOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; GW 655652; INDAZOLYPYRIMIDINE; PROTEIN TYROSINE KINASE INHIBITOR; SCATTER FACTOR; SEMAXANIB; SUNITINIB; UNCLASSIFIED DRUG; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 ANTIBODY; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 3 ANTIBODY; VASCULOTROPIN ANTIBODY; VASCULOTROPIN C; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3; VATALANIB;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; APOPTOSIS; BLAST CELL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG POTENTIATION; DRUG TARGETING; EDITORIAL; GENE THERAPY; HEMATOLOGIC MALIGNANCY; HUMAN; IN VITRO STUDY; LEUKEMIA CELL; LYMPHANGIOGENESIS; MONOTHERAPY; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TREATMENT OUTCOME; TUMOR GROWTH;

CELL LINE, TUMOR; HEMATOLOGIC NEOPLASMS; HUMANS; LYMPHANGIOGENESIS; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 63349091482     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2008.12.009     Document Type: Editorial

References (27)

1. Saharinen P., Tammela T., Karkkainen M.J., and Alitalo K. Lymphatic vasculature: development, molecular regulation and role in tumor metastasis and inflammation. Trends Immunol 25 (2004) 387-395
2. Karpanen T., and Alitalo K. Lymphatic vessels as targets of tumor therapy?. J Exp Med 194 (2001) F37-F42
3. Gombos Z., Xu X., Chu C.S., Zhang P.J., and Acs G. Peritumoral lymphatic in early-stage squamous cell carcinoma of the uterine cervix. Clin Cancer Res 11 (2005) 8364-8371
4. Hirakawa S., Kodama S., Kunstfeld R., Kajiya K., Borwn L.F., and Detmar M. VEGF-a induces tumor and sentinel lymph node lymphangiogenesis and promotes lymphatic metastasis. J Exp Med 201 (2005) 1089-1099
5. Kadowaki I., Ichinohasama R., Harigae H., Ishizawa K., Okitsu Y., Kameoka J., et al. Accelerated lymphangiogenesis in malignant lymphoma: possible role of VEGF-A and VEGF-C. Br J Haematol 130 (2005) 869-877
6. Salven P., Lymboussaki A., Heikkila P., Jaaskela-Saari H., Enholm B., Aase K., et al. Vascular endothelial growth factor VEGF-B and VEGF-C are expressed in human tumors. Am J Pathol 153 (1998) 103-108
7. Dias S., Choi N., Alitalo K., and Rafii S. Vascular endothelial growth factor (VEGF)-C signaling through FLT4 (VEGFR-3) mediates leukemic cell proliferation, survival, and resistance to chemotherapy. Blood 99 (2002) 2179-2184
8. Fielder W., Graeven U., Ergun S., Verago S., Kilic N., Stockschlader M., et al. Expression of FLT4 and its ligand VEGF-C in acute myeloid leukemia. Leukemia 11 (1997) 1234-1237
9. Liersch R., Schliemann C., Bieker R., Hintelmann H., Buechner T., Berdel W.E., et al. Expression of VEGF-C and its receptor VEGFR-3 in the bone marrow of patients with acute myeloid leukemia. Leuk Res 32 (2008) 954-961
10. Hou H.A., Chou W.C., Lin L.I., Tang J.L., Tseng M.H., Huang C.F., et al. Expression of angiopoietins, and vascular endothelial growth factors and their clinical significance in acute myeloid leukemia. Leuk Res 32 (2008) 904-912
11. De Jonge H.J.M., Weidenaar A.C., ter Elst A., Boezen H.M., Scherpen F.J.C., Bouma-Tersteege J.C.A., et al. Endogenous vascular endothelial growth factor-C expression is associated with decreased drug responsiveness in childhood acute myeloid leukemia. Clin Cancer Res 14 (2008) 924-930
12. Lee C.Y., Tien H.F., Hu C.Y., Chou W.C., and Lin L.I. Marrow angiogenesis-associated factors as prognostic biomarkers in patients with acute myelogeneous leukaemia. Br J Cancer 97 (2007) 877-882
13. Nowicki M., Ostalska-Nowicka D., Kaczmarek E., Miskowiak B., and Witt M. Vascular endothelial growth factor-C-a potent risk factor in childhood acute lymphoblastic leukaemia: an immunocytochemical approach. Histopathology 49 (2006) 170-177
14. Vacca A., Ria R., Ribatti D., Semeraro F., Djonov V., Di Raimondo F., et al. A paracrine loop in the vascular endothelial growth factor pathway triggers tumor angiogenesis and growth in multiple myeloma. Haematologica 88 (2003) 176-185
15. Ferrara N., Hillan K.J., Gerber H.P., and Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3 (2004) 391-400
16. Karp J.E., Gojo I., Pili R., Gocke C.D., Greer J., Guo C., et al. Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogeneous leukemias: therapy with sequential 1-beta-d-arabinofuranosylcytosine, mitoxantrone, and bevacizumab. Clin Cancer Res 10 (2004) 3577-3585
17. Zahiragic L., Schliemann C., Bieker R., Thoennissen N.H., Burow K., Kramer K., et al. Bevacizumab reduces VEGF expression in patients with relapsed and refractory acute myleoid leukemia without clinical antileukemic activity. Leukemia 21 (2007) 1310-1312
18. Cursiefen C., Chen L., Borges L.P., Jackson D., Cao J., Radziejwski C., et al. VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment. J Clin Invest 113 (2004) 1040-1050
19. Skobe M., and Detmar M. Structure, function, and molecular control of the skin lymphatic system. J Invest Dermatol Symp Proc 5 (2000) 14-19
20. Fiedler W., Mester R., Tinnefeld H., Loges S., Staib P., Duhrsen U., et al. A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia. Blood 102 (2003) 2763-2767
21. Roboz G.J., Giles F.J., List A.F., Cortes J.E., Carlin R., Kowalski M., et al. Phase I study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndrome. Leukemia 20 (2006) 952-957
22. Lin B., Podar K., Gupta D., Tai Y.T., Li S., Weller E., et al. The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment. Cancer Res 62 (2002) 5019-5026
23. Fiedler W., Serve H., Dohner H., Schwittay M., Ottmann O.G., O'Farrell, et al. A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood 105 (2005) 986-993
24. Podar K., and Anderson K.C. The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications. Blood 105 (2005) 1383-1395
25. Roberts N., Kloos B., Cassella M., Podgrabinska S., Persaud K., Wu Y., et al. Inhibition of VEGFR-3 activation with the antagonistic antibody more potently suppresses lymph node and distant metastases than inactivation of VEGFR-2. Cancer Res 66 (2006) 2650-2657
26. Kajiya K., Hirakawa S., Ma B., Drinnenberg I., and Detmar M. Hepatocyte growth factor promotes lymphatic vessel formation and function. EMBO J 24 (2005) 2885-2895
27. Morisada T., Oike Y., Yamada Y., Urano T., Akao M., Kuboya Y., et al. Angiopoietin-1 promotes LYVE-1 positive lymphatic vessel formation. Blood 105 (2005) 4649-4656